Background: ALKi represent the standard 1st- and 2nd -line treatment (Tx) for ALK+ aNSCLC patients (pts). The value of ALKi in the 3rd-line setting is unclear. We retrospectively assessed the real-world impact of a 3rd -line ALKi vs. non-ALKi Tx in ALK+ aNSCLC pts... Conclusions: Following progression on a 2ndALKi, OS and TNT were numerically higher for pts receiving a 3rd ALKi, but statistically NS. Extensive exposure of pts in the non-ALKi Tx Gr to an ALKi at a later stage might have impacted these results. Further studies are required to identify patients likely to benefit from ALKi after progressing on 2 or more ALKi Tx lines. READ ARTICLE
Journal of Clinical Oncology DOI:10.1200/JCO.2020.38.15_suppl.e21685
Authors: Natalie Maimon, Elizabeth Dudnik, Yakir Rottenberg, Noa Popovits-Hadari, Noam Asna, Mira Wollner, Alona Zer, Maya Gottfried, Moshe Mishaeli, Yulia Rovitsky-Gelis, Anastasiya Lobachov, Amir Onn, Damien Urban, Mor Tal Moskovitz, Jair Bar, Israel Lung Cancer Group